Reviews Bupropion Hcl


No reviews yet.

Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010





Other reviews about Bupropion Hcl on wordpress

Bupropion till sonant tobaccoy
  by stellaamnesther
Bangstromsically these drugs are antidePressants and are Time-honored versus patients as regards mince-evaporate insignifieration concern is similarly utilized headed for ease bourgeoisie bring to emanation. Bupropion dealings nigh […]


Bupropion till sonant tobaccoy
  by stellaamnesther
Bangstromsically these drugs are antidePressants and are Time-honored versus patients as regards mince-evaporate insignifieration concern is similarly utilized headed for ease bourgeoisie bring to emanation. Bupropion dealings nigh […]


Seizures Induced With Wellbutrin
  by Amy Philo
Paragraphs 5 through 7 read: "Results: The results show that administration of IP bupropion HCl [Wellbutrin] alone induced seizures in mice in a dose-dependent manner, with the 120 […]


Antidepressants, shooting rampages, suicide and senseless violence
  by neighborhoodwatcher
Thank you for clicking this link to find out more. Ever since the new class of antidepressants hit the market in the mid-80s, we have stood by and watched […]


Craps Hilton casino resort atlantic city
  by tasialcraneb
This long-term change was prevented when lithium was given continuously throughout show poker the period of dopamine infusion, but not when lithium was given in divided doses, showing […]


medication take II: Welbutrin (Bupropion HCL XL)
  by breeze1770
As stated in my last post the Xanax(alprazolam) was working well for severe, accute anxiety. I didn't want to keep taking it as often as I was because […]


Wellbutrin gives me insomnia
  by Alice
Three months ago I told my friends I have depression and anxiety. The conversation went dead for a while, but they returned to normal conversation as if I […]


NO DRUGS FOR YOU!!
  by breeze1770
The Bupropion HCL triggered hives and a closing of the throat. I still have some issue with hives, but the throat thing was clear in a day. It […]


Buspar and pain management
  by febidone
I everytime found at my % in those applications. Human disturbances have confused savings about the actonel of opinions. An in error response generic sr agreed that wholly […]


Buspar grapefruit
  by febidone
Specialized drugs have reported that night federally handcuffs dry equipment in diagnoses who include onward have tablet. My kernel who I am actually not leads me became the […]



Other reviews about Bupropion Hcl on web:

Bupropion (also known as Wellbutrin, Zyban, Voxra, Budeprion, or Aplenzin; formerly known as amfebutamone) is an atypical antidepressant and smoking cessation aid. Bupropion - Wikipedia, the free encyclopedia


Learn about the prescription medication Zyban (Bupropion Hcl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Zyban (Bupropion Hcl) Drug Information: Uses, Side Effects, Drug ...


Learn about the prescription medication Wellbutrin (Bupropion Hcl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Wellbutrin (Bupropion Hcl) Drug Information: Uses, Side Effects ...


Wellbutrin is an antidepressant also sold as Zyban to help people quit smoking. The generic name is Bupropion HCl. Wellbutrin Medication Profile - Zyban - Bupropion HCl - antidepressant


Bupropion HCL is your direct source for the cheapest Bupropion on the net. Buy cheap bupropion online. Bupropion HCL - Information and Pricing


bupropion side effects sr hcl weight loss ... Bupropion HCL benefit and side effects by Ray Sahelian, M.D. Bupropion is a norepinephrine and dopamine uptake inhibitor that has ... Bupropion side effects and benefit by Ray Sahelian, M.D.


BuPROPion HCl is an antidepressant used to treat depression. Side effects and interactions are available at drugstore.com; plus get home delivery from a trusted and licensed U ... BuPROPion HCl - drugstore.com. Low prices, side effects, interactions.


If there is not adequate improvement after several weeks, the dose may be increased to a maximum of 522 mg once a day in the morning (equivalent to 450 mg bupropion HCl). Bupropion Information from Drugs.com


Find patient medical information for Bupropion HCl Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Bupropion HCl Oral : Uses, Side Effects, Interactions, Pictures ...


Bupropion HCl (byoo-PRO-pee-ahn HIGH-droe-KLOR-ide) Trade Name(s): Wellbutrin; Tablets ; 75 mg; Tablets ; 100 mg Wellbutrin SR; Tablets, sustained-release Bupropion HCl





Featured Reviews

Reviews Lexiscan

Lexiscan Drug Description Lexiscan® (regadenoson) Injection for Intravenous Administration DRUG DESCRIPTION What are the possible side effects of regadenoson (Lexiscan)? Get emergency medical help if you have any of these signs...
Read More  |  Review This
Reviews Prilosec

Prilosec Drug Description PRILOSEC (omeprazole) Delayed-Release Capsules PRILOSEC (omeprazole magnesium) For Delayed Release Oral suspension DRUG DESCRIPTION What are the possible side effects of omeprazole (Prilosec, Prilosec...
Read More  |  Review This
Reviews Human)

HyperHep B Drug Description HyperHEP B™ S/D Hepatitis B Immune Globulin (Human) Solvent/Detergent Treated DRUG DESCRIPTION What are the possible side effects of hepatitis B immune globulin (HepaGam B, HepaGam B NovaPlus,...
Read More  |  Review This
Reviews Potassium Chloride

Slow-K Drug Description SLOW-K (potassium chloride) Tablet, Extended Release DRUG DESCRIPTION Slow-K, potassium chloride extended-release tablets USP, is a sugar-coated (not enteric-coated) tablet for oral administration, containing 600...
Read More  |  Review This
Reviews Promethazine HCl Injection

Promethazine HCl Injection Drug Description Promethazine Hydrochloride Injection, USP DRUG DESCRIPTION What are the possible side effects of promethazine injection (Adgan, Anergan 50, Antinaus 50, Pentazine, Phenergan)? Get emergency...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....